Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00464269




Registration number
NCT00464269
Ethics application status
Date submitted
19/04/2007
Date registered
23/04/2007
Date last updated
21/07/2022

Titles & IDs
Public title
Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures
Scientific title
An International, Double-blind, Parallel-group, Placebo-controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures
Secondary ID [1] 0 0
2006-006345-14
Secondary ID [2] 0 0
N01253
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Epilepsy 0 0
Condition category
Condition code
Neurological 0 0 0 0
Epilepsy
Neurological 0 0 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional(has expanded access)
Description of intervention(s) / exposure
Other interventions - Placebo
Treatment: Drugs - Brivaracetam 2.5 mg
Treatment: Drugs - Brivaracetam 10 mg
Treatment: Drugs - Brivaracetam 25 mg

Placebo comparator: Placebo - Matching Placebo tablets administered twice a day. Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 12-week Treatment Period.

Experimental: Brivaracetam 5 mg/day - Brivaracetam 5 mg/day, 2.5 mg administered twice a day. Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 5 mg /day in a double-blinded way for the 12-week Treatment Period.

Experimental: BRV 20mg/day - Brivaracetam 20 mg/day, 10 mg administered twice a day. Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 20 mg /day in a double-blinded way for the 12-week Treatment Period.

Experimental: BRV 50mg/day - Brivaracetam 50 mg/day, 25 mg administered twice a day. Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg /day, in a double-blinded way for the 12-week Treatment Period.


Other interventions: Placebo
* Active Substance: Placebo
* Pharmaceutical Form: Film-coated tablet
* Concentration: 2.5 mg, 10 mg and 25 mg
* Route of Administration: Oral use

Treatment: Drugs: Brivaracetam 2.5 mg
* Active Substance: Brivaracetam
* Pharmaceutical Form: Film-coated tablet
* Concentration: 2.5 mg
* Route of Administration: Oral use

Treatment: Drugs: Brivaracetam 10 mg
* Active Substance: Brivaracetam
* Pharmaceutical Form: Film-coated tablet
* Concentration: 10 mg
* Route of Administration: Oral use

Treatment: Drugs: Brivaracetam 25 mg
* Active Substance: Brivaracetam
* Pharmaceutical Form: Film-coated tablet
* Concentration: 25 mg
* Route of Administration: Oral use
Intervention code [1] 0 0
Other interventions
Intervention code [2] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Partial Onset Seizure (Type I) Frequency Per Week Over the 12-week Treatment Period
Timepoint [1] 0 0
Baseline to 12-week Treatment Period
Secondary outcome [1] 0 0
Responder Rate for Partial Onset Seizure (Type I) Frequency Per Week Over the 12-week Treatment Period
Timepoint [1] 0 0
Baseline to 12-week Treatment Period
Secondary outcome [2] 0 0
All Seizure Frequency (Type I+II+III) Per Week Over the 12-week Treatment Period
Timepoint [2] 0 0
Baseline to 12-week Treatment Period
Secondary outcome [3] 0 0
Percent Change From Baseline to the 12-week Treatment Period in Partial Onset Seizure (Type I) Frequency Per Week
Timepoint [3] 0 0
Baseline to 12-week Treatment Period
Secondary outcome [4] 0 0
Categorized Percentage Change From Baseline in Seizure Frequency for Partial Onset Seizure (Type I) Over the 12-week Treatment Period
Timepoint [4] 0 0
Baseline to 12-week Treatment Period
Secondary outcome [5] 0 0
Seizure Freedom Rate (All Seizure Types) Over the 12-week Treatment Period
Timepoint [5] 0 0
Baseline to 12-week Treatment Period
Secondary outcome [6] 0 0
Time to First Type I Seizure During the 12-week Treatment Period
Timepoint [6] 0 0
Baseline to 12-week Treatment Period
Secondary outcome [7] 0 0
Time to Fifth Type I Seizure During the 12-week Treatment Period
Timepoint [7] 0 0
Baseline to 12-week Treatment Period
Secondary outcome [8] 0 0
Time to Tenth Type I Seizure During the 12-week Treatment Period
Timepoint [8] 0 0
Baseline to 12-week Treatment Period
Secondary outcome [9] 0 0
Reduction of Type IC/Type I Seizure Frequency Ratio From Baseline to the 12- Week Treatment Period
Timepoint [9] 0 0
Baseline to 12-week Treatment Period
Secondary outcome [10] 0 0
Change From Baseline to the 12-week Treatment Period in Total Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
Timepoint [10] 0 0
Baseline to 12-week Treatment Period
Secondary outcome [11] 0 0
Change From Baseline to the 12-week Treatment Period in Seizure Worry Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
Timepoint [11] 0 0
Baseline to 12-week Treatment Period
Secondary outcome [12] 0 0
Change From Baseline to the 12-week Treatment Period in Daily Activities / Social Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
Timepoint [12] 0 0
Baseline to 12-week Treatment Period
Secondary outcome [13] 0 0
Change From Baseline to the 12-week Treatment Period in Hospital Anxiety Score
Timepoint [13] 0 0
Baseline to 12-week Treatment Period
Secondary outcome [14] 0 0
Change From Baseline to the 12-week Treatment Period in Hospital Depression Score
Timepoint [14] 0 0
Baseline to 12-week Treatment Period
Secondary outcome [15] 0 0
Patient's Global Evaluation Scale (P-GES) Evaluated at Last Visit or Early Discontinuation Visit
Timepoint [15] 0 0
Baseline to Last Visit or Early Discontinuation Visit in the 12-week Treatment Period
Secondary outcome [16] 0 0
Investigator's Global Evaluation Scale (I-GES) Evaluated at Last Visit or Early Discontinuation Visit
Timepoint [16] 0 0
Baseline to Last Visit or Early Discontinuation Visit in the 12-week Treatment Period
Secondary outcome [17] 0 0
Change From Baseline to the 12-week Treatment Period in Energy/Fatigue Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
Timepoint [17] 0 0
From Baseline to 12-week Treatment Period
Secondary outcome [18] 0 0
Change From Baseline to the 12-week Treatment Period in Emotional Well-Being Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
Timepoint [18] 0 0
From Baseline to 12-week Treatment Period
Secondary outcome [19] 0 0
Change From Baseline to the 12-week Treatment Period in Cognitive Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
Timepoint [19] 0 0
From Baseline to 12-week Treatment Period
Secondary outcome [20] 0 0
Change From Baseline to the 12-week Treatment Period in Medication Effects Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
Timepoint [20] 0 0
From Baseline to 12-week Treatment Period
Secondary outcome [21] 0 0
Change From Baseline to the 12-week Treatment Period in Overall Quality of Life Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
Timepoint [21] 0 0
From Baseline to 12-week Treatment Period
Secondary outcome [22] 0 0
Change From Baseline to the 12-week Treatment Period in Health Status of Life Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
Timepoint [22] 0 0
From Baseline to 12-week Treatment Period

Eligibility
Key inclusion criteria
* Subjects were 16 to 70 years, both inclusive. Subjects under 18 years of age were only included where legally permitted and ethically accepted
* Subjects with well-characterized focal epilepsy or epileptic syndrome according to the International League Against Epilepsy (ILAE) classification
* Subjects had a history of partial onset seizures (POS) whether or not secondarily generalized (Type I seizures according to the ILAE classification)
* Subjects had at least 2 POS whether or not secondarily generalized per month during the 3 months preceding Visit 1 (V1)
* Subjects had at least 8 POS whether or not secondarily generalized during the 8-Week Baseline Period
* Subjects were uncontrolled while treated by 1 to 2 permitted concomitant antiepileptic drug(s) (AEDs). Vagal nerve stimulation (VNS) was allowed and was not counted as a concomitant AED
Minimum age
16 Years
Maximum age
70 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* History or presence of seizures occurring only in clusters (too frequently or indistinctly separated to be reliably counted) before Visit 3
* History or presence of status epilepticus during the year preceding Visit 1 or during Baseline

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/09/2007
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/01/2009
Sample size
Target
Accrual to date
Final
400
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Recruitment hospital [1] 0 0
- Chatswood
Recruitment hospital [2] 0 0
- Randwick
Recruitment hospital [3] 0 0
- Woodville
Recruitment hospital [4] 0 0
- Clayton
Recruitment hospital [5] 0 0
- Fitzroy
Recruitment hospital [6] 0 0
- Parkville
Recruitment hospital [7] 0 0
- Adelaide
Recruitment hospital [8] 0 0
- West Heidelberg
Recruitment postcode(s) [1] 0 0
- Chatswood
Recruitment postcode(s) [2] 0 0
- Randwick
Recruitment postcode(s) [3] 0 0
- Woodville
Recruitment postcode(s) [4] 0 0
- Clayton
Recruitment postcode(s) [5] 0 0
- Fitzroy
Recruitment postcode(s) [6] 0 0
- Parkville
Recruitment postcode(s) [7] 0 0
- Adelaide
Recruitment postcode(s) [8] 0 0
- West Heidelberg
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
District of Columbia
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Kansas
Country [8] 0 0
United States of America
State/province [8] 0 0
Kentucky
Country [9] 0 0
United States of America
State/province [9] 0 0
Maryland
Country [10] 0 0
United States of America
State/province [10] 0 0
Massachusetts
Country [11] 0 0
United States of America
State/province [11] 0 0
Michigan
Country [12] 0 0
United States of America
State/province [12] 0 0
Minnesota
Country [13] 0 0
United States of America
State/province [13] 0 0
Mississippi
Country [14] 0 0
United States of America
State/province [14] 0 0
Missouri
Country [15] 0 0
United States of America
State/province [15] 0 0
New York
Country [16] 0 0
United States of America
State/province [16] 0 0
Ohio
Country [17] 0 0
United States of America
State/province [17] 0 0
Oregon
Country [18] 0 0
United States of America
State/province [18] 0 0
Pennsylvania
Country [19] 0 0
United States of America
State/province [19] 0 0
South Carolina
Country [20] 0 0
United States of America
State/province [20] 0 0
Tennessee
Country [21] 0 0
United States of America
State/province [21] 0 0
Texas
Country [22] 0 0
United States of America
State/province [22] 0 0
Utah
Country [23] 0 0
United States of America
State/province [23] 0 0
Virginia
Country [24] 0 0
United States of America
State/province [24] 0 0
Washington
Country [25] 0 0
United States of America
State/province [25] 0 0
Wisconsin
Country [26] 0 0
Brazil
State/province [26] 0 0
Campinas
Country [27] 0 0
Brazil
State/province [27] 0 0
Curitiba
Country [28] 0 0
Brazil
State/province [28] 0 0
Florianópolis
Country [29] 0 0
Brazil
State/province [29] 0 0
Porto Alegre
Country [30] 0 0
Brazil
State/province [30] 0 0
Ribeirao Preto
Country [31] 0 0
Brazil
State/province [31] 0 0
Salvador
Country [32] 0 0
Brazil
State/province [32] 0 0
Sao Jose do Rio Preto
Country [33] 0 0
Brazil
State/province [33] 0 0
Sao Paulo
Country [34] 0 0
Brazil
State/province [34] 0 0
São Paulo
Country [35] 0 0
Canada
State/province [35] 0 0
Alberta
Country [36] 0 0
Canada
State/province [36] 0 0
Quebec
Country [37] 0 0
Mexico
State/province [37] 0 0
DF
Country [38] 0 0
Mexico
State/province [38] 0 0
NL
Country [39] 0 0
Mexico
State/province [39] 0 0
Aguascalientes
Country [40] 0 0
Mexico
State/province [40] 0 0
Chihuahua
Country [41] 0 0
Mexico
State/province [41] 0 0
Mexico DF
Country [42] 0 0
Mexico
State/province [42] 0 0
Monterrey
Country [43] 0 0
Mexico
State/province [43] 0 0
Nuevo León
Country [44] 0 0
Mexico
State/province [44] 0 0
San Luis Potosi

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
UCB Pharma
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
UCB Clinical Trial Call Center
Address 0 0
+1 877 822 9493 (UCB)
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

TypeCitations or Other Details
Journal Biton V, Berkovic SF, Abou-Khalil B, Sperling MR, ... [More Details]
Journal Toledo M, Whitesides J, Schiemann J, Johnson ME, E... [More Details]
Journal Ben-Menachem E, Mameniskiene R, Quarato PP, Klein ... [More Details]
Journal Brodie MJ, Whitesides J, Schiemann J, D'Souza J, J... [More Details]
Journal Mukuria C, Young T, Keetharuth A, Borghs S, Brazie... [More Details]
Journal Moseley BD, Sperling MR, Asadi-Pooya AA, Diaz A, E... [More Details]
Journal Brandt C, Borghs S, Elmoufti S, Mueller K, Townsen... [More Details]
Journal Klein P, Johnson ME, Schiemann J, Whitesides J. Ti... [More Details]
Journal Asadi-Pooya AA, Sperling MR, Chung S, Klein P, Dia... [More Details]
Journal Benbadis S, Klein P, Schiemann J, Diaz A, Elmoufti... [More Details]
Journal Brodie MJ, Fakhoury T, McDonough B, Colson AO, Sto... [More Details]
Journal Klein P, Laloyaux C, Elmoufti S, Gasalla T, Martin... [More Details]
Journal Moseley BD, Dimova S, Elmoufti S, Laloyaux C, Asad... [More Details]
Journal Ryvlin P, Dimova S, Elmoufti S, Floricel F, Laloya... [More Details]

Results are available at https://clinicaltrials.gov/study/NCT00464269